Palisade Bio (PALI) said Friday it began dosing ulcerative colitis patients in the final cohort of its phase 1a/b study of PALI-2108.
The company said it had completed five single ascending dose cohorts and three of four multiple ascending dose cohorts, with no serious adverse events or treatment-related adverse events tied to lab results or EKGs.
Palisade Bio said it plans to report topline data in H1.
Shares of the company were up 3% in recent Friday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.